Andrea G Bowden-evans, CRNP Clinical Nurse Specialist - Family Health Medicare: Not Enrolled in Medicare Practice Location: 1325 Mcfarland Blvd Ste 206, Northport, AL 35476 Phone: 205-330-4959 Fax: 205-330-4992 |
News Archive
Scientists from The University of Manchester working with IBM Research have identified a key biological mechanism that for the first time explains why women with dense breast tissue are at greater risk of developing breast cancer.
LifeVantage Corporation, the maker of Protandim®, a clinically proven, science-based therapy for oxidative stress, announced today that a new peer-reviewed study involving Protandim® was published in the scientific journal PLoS ONE. The study, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress tumors in mice. That ability was previously demonstrated by the authors in a study involving a mouse two-stage model of chemically-induced skin cancer.
The oil spill ravaging the Gulf of Mexico has inflicted widespread psychological distress among coastal residents of Louisiana, Mississippi, Alabama and Florida, etching scars even deeper than those whipped by Hurricane Katrina, according to a survey by Ochsner Health System, a nonprofit, academic healthcare delivery system.
Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of those appropriate for targeted treatment and monitoring genetic changes that occur during therapy. A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.
› Verified 9 days ago